Pemmaraju N - Search Results

1

Targeting CD123 in BPDCN: an emerging field.

DiPippo AJ, Wilson NR, Pemmaraju N. DiPippo AJ, et al. Among authors: pemmaraju n. Expert Rev Hematol. 2021 Nov;14(11):993-1004. doi: 10.1080/17474086.2021.1988848. Epub 2021 Oct 29. Expert Rev Hematol. 2021. PMID: 34607517 Review.

2

Blastic plasmacytoid dendritic cell neoplasm.

Pemmaraju N. Pemmaraju N. Clin Adv Hematol Oncol. 2016 Apr;14(4):220-2. Clin Adv Hematol Oncol. 2016. PMID: 27166602 No abstract available.

3

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Pemmaraju N, Gupta V, Thompson MA, Lane AA. Pemmaraju N, et al. Curr Hematol Malig Rep. 2016 Dec;11(6):462-467. doi: 10.1007/s11899-016-0340-3. Curr Hematol Malig Rep. 2016. PMID: 27492117 Review.

4

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond.

Pemmaraju N. Pemmaraju N. Curr Hematol Malig Rep. 2017 Dec;12(6):510-512. doi: 10.1007/s11899-017-0425-7. Curr Hematol Malig Rep. 2017. PMID: 29064022 Review. No abstract available.

5

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN.

Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Pemmaraju N, et al. Curr Hematol Malig Rep. 2017 Dec;12(6):592-597. doi: 10.1007/s11899-017-0422-x. Curr Hematol Malig Rep. 2017. PMID: 29064025 Review.

6

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. DiNardo CD, et al. Among authors: pemmaraju n. Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23. Am J Hematol. 2018. PMID: 29218851 Free article.

7

Early detection of transformation to BPDCN in a patient with MDS.

Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Chamoun K, et al. Among authors: pemmaraju n. Exp Hematol Oncol. 2018 Oct 6;7:26. doi: 10.1186/s40164-018-0117-6. eCollection 2018. Exp Hematol Oncol. 2018. PMID: 30323983 Free PMC article.

8

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community.

Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Pemmaraju N, et al. Curr Hematol Malig Rep. 2018 Dec;13(6):581-587. doi: 10.1007/s11899-018-0490-6. Curr Hematol Malig Rep. 2018. PMID: 30338458 Review.

9

Treatment advances in blastic plasmacytoid dendritic cell neoplasm.

Pemmaraju N. Pemmaraju N. Clin Adv Hematol Oncol. 2019 Apr;17(4):207-209. Clin Adv Hematol Oncol. 2019. PMID: 31188810 No abstract available.

10

Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm.

Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Sukswai N, et al. Among authors: pemmaraju n. Am J Surg Pathol. 2019 Oct;43(10):1429-1437. doi: 10.1097/PAS.0000000000001316. Am J Surg Pathol. 2019. PMID: 31261288

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

387 results

Search Page